메뉴 건너뛰기




Volumn 91, Issue 2, 2011, Pages 76-80

Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics

Author keywords

Breast neoplasms; Fluorescence in situ hybridization; Human epidermal growth factor receptor 2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; HER2 PROTEIN, HUMAN;

EID: 84869211240     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.02.003     Document Type: Article
Times cited : (4)

References (25)
  • 1
    • 0037099732 scopus 로고    scopus 로고
    • Evaluation of HER-2/neu gene amplification and overexpression
    • Press MF, Slamon DJ, Flora KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression. J Clin Oncol, 2002, 20: 3095-3105.
    • (2002) J Clin Oncol , vol.20 , pp. 3095-3105
    • Press, M.F.1    Slamon, D.J.2    Flora, K.J.3
  • 2
    • 1542647611 scopus 로고    scopus 로고
    • Targeted therapy for cancer: the HER-2/neu and herceptin story
    • Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and herceptin story. Clin Leadersh Manag, Rev, 2003, 17: 333-340.
    • (2003) Clin Leadersh Manag, Rev , vol.17 , pp. 333-340
    • Ross, J.S.1    Gray, G.S.2
  • 3
    • 0035257578 scopus 로고    scopus 로고
    • New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin)
    • Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol, 2001, 28 Suppl 3: 1-12.
    • (2001) Semin Oncol , vol.28 , Issue.SUPPL. 3 , pp. 1-12
    • Nabholtz, J.M.1    Slamon, D.2
  • 4
    • 0037023986 scopus 로고    scopus 로고
    • Real-world performance of HER2 testing: national surgical adjuvant breast and bowel project experience
    • Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst, 2002, 94: 852-854.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 852-854
    • Paik, S.1    Bryant, J.2    Tan-Chiu, E.3
  • 5
    • 0037024478 scopus 로고    scopus 로고
    • Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    • Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst, 2002, 94: 855-857.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 855-857
    • Roche, P.C.1    Suman, V.J.2    Jenkins, R.B.3
  • 6
    • 17844376512 scopus 로고    scopus 로고
    • Comparison of Immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice
    • Dolan M, Snover D. Comparison of Immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol, 2005, 123: 766-770.
    • (2005) Am J Clin Pathol , vol.123 , pp. 766-770
    • Dolan, M.1    Snover, D.2
  • 7
    • 33745153139 scopus 로고    scopus 로고
    • Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2 + in immunohistochemical analysis
    • Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2 + in immunohistochemical analysis. Eur J Cancer, 2006, 42: 1501-1506.
    • (2006) Eur J Cancer , vol.42 , pp. 1501-1506
    • Merola, R.1    Mottolese, M.2    Orlandi, G.3
  • 8
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer
    • Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med, 2005, 353: 1673-1684.
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 9
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344: 783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 10
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    • Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369: 29-36.
    • (2007) Lancet , vol.369 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3
  • 11
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    • Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002, 20: 719-726.
    • (2002) J Clin Oncol , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3
  • 12
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005, 353: 1659-1672.
    • (2005) N Engl J Med , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 13
    • 33344478381 scopus 로고    scopus 로고
    • Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    • Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med, 2006 354: 809-820.
    • (2006) N Engl J Med , vol.354 , pp. 809-820
    • Joensuu, H.1    Kellokumpu-Lehtinen, P.L.2    Bono, P.3
  • 14
    • 0042566053 scopus 로고    scopus 로고
    • Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
    • Lal P, Salazar PA, Ladanyi M, et al. Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification J Mol Diagn, 2003, 5: 155-159.
    • (2003) J Mol Diagn , vol.5 , pp. 155-159
    • Lal, P.1    Salazar, P.A.2    Ladanyi, M.3
  • 15
    • 3042622482 scopus 로고    scopus 로고
    • HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
    • Owens MA, Horten BC, Da Silva MM. HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 2004, 5: 63-69.
    • (2004) Clin Breast Cancer , vol.5 , pp. 63-69
    • Owens, M.A.1    Horten, B.C.2    Da Silva, M.M.3
  • 16
    • 73649147338 scopus 로고    scopus 로고
    • HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry
    • Kovács A, Stenman G. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol Res Pract, 2010, 206: 39-42.
    • (2010) Pathol Res Pract , vol.206 , pp. 39-42
    • Kovács, A.1    Stenman, G.2
  • 17
    • 17144414443 scopus 로고    scopus 로고
    • Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer
    • Lottner C, Schwarz S, Diermeier S, et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol, 2005, 205: 577-584.
    • (2005) J Pathol , vol.205 , pp. 577-584
    • Lottner, C.1    Schwarz, S.2    Diermeier, S.3
  • 18
    • 28544452873 scopus 로고    scopus 로고
    • Histopathologic characteristics predicting HER-2/neu amplification in breast cancer
    • Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J, 2005, 11: 433-439.
    • (2005) Breast J , vol.11 , pp. 433-439
    • Prati, R.1    Apple, S.K.2    He, J.3
  • 19
    • 2142758687 scopus 로고    scopus 로고
    • HER-2 testing in breast cancer using parallel tissue-based methods
    • Yaziji H, Goldstein L, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 2004, 291: 1972-1977.
    • (2004) JAMA , vol.291 , pp. 1972-1977
    • Yaziji, H.1    Goldstein, L.2    Barry, T.S.3
  • 20
    • 77957101699 scopus 로고    scopus 로고
    • Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India
    • Panjwani P, Epari S, Karpate A, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India. Indian J Med Res, 2010, 132: 287-294.
    • (2010) Indian J Med Res , vol.132 , pp. 287-294
    • Panjwani, P.1    Epari, S.2    Karpate, A.3
  • 21
    • 0346500480 scopus 로고    scopus 로고
    • Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay
    • Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol, 2004, 121: 70-77.
    • (2004) Am J Clin Pathol , vol.121 , pp. 70-77
    • Varshney, D.1    Zhou, Y.Y.2    Geller, S.A.3
  • 22
    • 54449091620 scopus 로고    scopus 로고
    • Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing
    • Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol, 2008, 26: 4869-4874.
    • (2008) J Clin Oncol , vol.26 , pp. 4869-4874
    • Vanden Bempt, I.1    Van Loo, P.2    Drijkoningen, M.3
  • 23
    • 0037440261 scopus 로고    scopus 로고
    • Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
    • Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst, 2003, 95: 142-153.
    • (2003) J Natl Cancer Inst , vol.95 , pp. 142-153
    • Konecny, G.1    Pauletti, G.2    Pegram, M.3
  • 24
    • 0038575385 scopus 로고    scopus 로고
    • Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer
    • Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 2003, 200: 290-297.
    • (2003) J Pathol , vol.200 , pp. 290-297
    • Witton, C.J.1    Reeves, J.R.2    Going, J.J.3
  • 25
    • 33847159947 scopus 로고    scopus 로고
    • HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive
    • Olsen DA, Østergaard B, Bokmand S, et al. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med, 2007, 45: 177-182.
    • (2007) Clin Chem Lab Med , vol.45 , pp. 177-182
    • Olsen, D.A.1    østergaard, B.2    Bokmand, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.